Genmab A/S focuses on developing innovative monoclonal antibodies to treat life-threatening and debilitating diseases, primarily in the field of oncology. The company's business model is underpinned by a highly profitable royalty-driven revenue stream from partnered blockbuster drugs, such as DARZALEX for multiple myeloma (partnered with Johnson & Johnson) and Kesimpta for multiple sclerosis (partnered with Novartis). In addition to its partnered portfolio, Genmab markets its own approved therapies, including EPKINLY and Tivdak, and maintains a robust clinical and pre-clinical pipeline. The company operates globally with key research and commercial sites in Denmark, the Netherlands, the United States, and Japan. Genmab utilizes its proprietary technology platforms—including DuoBody, HexaBody, DuoHexaBody, and HexElect—to sustain its competitive edge and transition toward a fully integrated global commercial organization.
